Under a tenth of people that would benefit from obesity jabs such as Wegovy can access them, states the World Health Organization as it issues its first recommendations on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for more widespread and fairer availability to GLP-1 medication.
Per forecasts, over two billion could be obese by 2030 if no action is taken.
"The new guidance affirms that excess weight is a chronic disease that can be treated with thorough and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are key barriers to universal access to the injections that can aid individuals in losing substantial body mass, notes the agency.
GLP-1 Therapy Scarcity
Even in the present most favorable case, the production of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of those who need them, according to the health organization.
The guideline calls on countries and companies to widen access, via measures like voluntary licensing.
Exclusive production rights on the active ingredient – the core ingredient of a leading brand – is due to expire in multiple nations in 2026.
The Way Weight-Loss Jabs Operate
The injections imitate a natural hormone to delay gastric emptying, suppress the appetite and enhance satiety so individuals reduce food intake.
People usually begin shedding pounds in the initial weeks of beginning the regular doses.
Evidence suggests people may see weight return within a year of stopping the drug, because their normal appetite come back.
Being above a healthy weight elevates your risk for developing health problems, like diabetes, heart disease, stroke, and some cancers.
Obesity concerns individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.
